This Article Full Text Full Text (PDF) All Versions of this Article: 2050304v1 14/5/917    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeh, I. Articles by Altman, R. B. Search for Related Content PubMed PubMed Citation Articles by Yeh, I. Articles by Altman, R. B. Social Bookmarking                   What's this?

Resources

Computational Analysis of Plasmodium falciparum Metabolism: Organizing Genomic Information to Facilitate Drug Discovery

¹ Department of Genetics, Stanford University, Stanford, California 94305, USA ² Department of Molecular Biology, University of Wyoming, Laramie, Wyoming 82071, USA ³ Computational Genomics Group, Research Programme, European Bioinformatics Institute, European Molecular Biology Laboratory Cambridge Outstation, Cambridge CB10 1SD, UK ⁴ Bioinformatics Research Group, SRI International, Menlo Park, California 94025, USA

Identification of novel targets for the development of more effective antimalarial drugs and vaccines is a primary goal of the Plasmodium genome project. However, deciding which gene products are ideal drug/vaccine targets remains a difficult task. Currently, a systematic disruption of every single gene in Plasmodium is technically challenging. Hence, we have developed a computational approach to prioritize potential targets. A pathway/genome database (PGDB) integrates pathway information with information about the complete genome of an organism. We have constructed PlasmoCyc, a PGDB for Plasmodium falciparum 3D7, using its annotated genomic sequence. In addition to the annotations provided in the genome database, we add 956 additional annotations to proteins annotated as "hypothetical" using the GeneQuiz annotation system. We apply a novel computational algorithm to PlasmoCyc to identify 216 "chokepoint enzymes." All three clinically validated drug targets are chokepoint enzymes. A total of 87.5% of proposed drug targets with biological evidence in the literature are chokepoint reactions. Therefore, identifying chokepoint enzymes represents one systematic way to identify potential metabolic drug targets.

⁵ Corresponding author.
E-MAIL russ.altman{at}stanford.edu; FAX (650) 725-3863.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. A. Rahman and D. Schomburg Observing local and global properties of metabolic pathways: 'load points' and 'choke points' in the metabolic networks Bioinformatics, July 15, 2006; 22(14): 1767 - 1774. [Abstract] [Full Text] [PDF]

				G. A. Biagini, P. Viriyavejakul, P. M. O'Neill, P. G. Bray, and S. A. Ward Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1841 - 1851. [Abstract] [Full Text] [PDF]

				P. D. Karp, C. A. Ouzounis, C. Moore-Kochlacs, L. Goldovsky, P. Kaipa, D. Ahren, S. Tsoka, N. Darzentas, V. Kunin, and N. Lopez-Bigas Expansion of the BioCyc collection of pathway/genome databases to 160 genomes Nucleic Acids Res., October 24, 2005; 33(19): 6083 - 6089. [Abstract] [Full Text] [PDF]

				J. W. Pinney, M. W. Shirley, G. A. McConkey, and D. R. Westhead metaSHARK: software for automated metabolic network prediction from DNA sequence and its application to the genomes of Plasmodium falciparum and Eimeria tenella Nucleic Acids Res., March 3, 2005; 33(4): 1399 - 1409. [Abstract] [Full Text] [PDF]